Health Care · Laboratory Analytical Instruments

TXG 10x Genomics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 177078797 filings
Russell 2000

TXG at a glance

10x Genomics, Inc. (TXG, SEC CIK 1770787) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), 10x Genomics, Inc. (TXG) reported revenue of $642.8 million (up 5.2% from FY2024) and a net loss of $43.5 million. Diluted EPS was -$0.35.
  • As of September 30, 2026, 36 institutional investment managers tracked by SignalX reported holding 10x Genomics, Inc. (TXG) shares worth $6.3 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Saxonov Serge on November 10, 2026 of 31,000 shares at $62.90 per share.
  • In the last 90 days, TXG insiders reported 0 open-market purchases ($0) and 25 open-market sales ($12.6M) on Form 4, a net sale of $12.6M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$642.8M
+5.2% vs prior year
Insiders · 90 days
0 buys · 25 sells
Net −$12.6M
13F holders
36 funds
$6.3B · +1 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: integrated life sciences technology products and software for analyzing biological systems with high resolution and scale
  • New acquisition in 2025: Scale Biosciences, adding QuantumScale single cell RNA and methylation kits to single cell portfolio
  • Strategic emphasis on expanding spatial portfolio with Visium CytAssist instrument and new Xenium analyzer for in situ RNA analysis
  • Employee count increased to 1,178 in 2025, including 332 in R&D and 473 in sales/marketing/support
  • Noteworthy: Sold 1,007 instruments and 424,000 consumable reactions in 2025, reflecting growth in consumable reactions despite slight instrument sales decline vs 2024

Risk Factors

  • Regulatory/legal risk: Patent litigation settlements with Vizgen (Feb 2025, $26M upfront) and Bruker (May 2025, $68M installments) impacting license and royalty revenue
  • Geopolitical/macroeconomic risk: Foreign currency fluctuations affecting revenue, mainly in euro, GBP, and JPY markets, causing realized/unrealized gains/losses of $4.6M in 2025
  • Operational/supply chain risk: $7.8M increase in inventory write-downs due to product mix changes and manufacturing cost pressures in 2025
  • Competitive/market disruption risk: Price declines of Spatial instruments caused 39% revenue drop ($35.9M) in 2025 amid competition and market pricing pressure
  • Financial/structural risk: Dependence on contingent consideration of up to $30M from Scale Bio acquisition, with fair value remeasured quarterly causing revenue and income fluctuation

Management Discussion & Analysis

  • Cash flow, buybacks, dividends, and capex data not included
  • Forward-looking statements caution on risks and uncertainties without specific guidance

AI summary of the TXG 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $150.7M, up $1.7M YoY, or 1%
  • Gross margin 75% vs 67% YoY, driven by lower inventory write-downs and product mix
  • Best segment: Single Cell consumables $93.1M, up $0.6M; worst: Spatial instruments $3.1M, down $4.0M
  • Cash and securities $575.7M, up $52.3M from December 31, 2025; nine-month operating cash flow $58.9M vs $95.3M
  • Outlook: fourth-quarter gross margin expected lower due to product mix; operating losses expected for the foreseeable future

Risk Factors

  • Newly added risk, AI Technologies: 2026 Sentira launch and third-party foundation-model dependencies introduced validation, data security and regulatory uncertainties
  • Most materially updated risk, Atera transition: shipments began September 2026, with Xenium and Visium revenue declines and expected margin pressure from instrument-heavy sales
  • Regulatory risk, clinical expansion: CLIA certification and California licensure required before patient testing, with inspections and validation potentially delaying launch
  • Market risk, research funding: NIH terminated approximately 700 grants totaling more than $2.4 billion in March 2025, pressuring customer purchases
  • Financial risk, currency exposure: approximately 27% of sales denominated in non-U.S. currencies, without a current hedging program

AI summary of the TXG 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Detailed revenue, earnings, guidance and operating metrics contained in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $150.7M, up 1%, with consumables growth offsetting instrument weakness
  • Gross margin 75% vs 67%, aided by lower inventory write-downs and favorable product mix
Filed Nov 2, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board additions: Ansuman Satpathy and Joseph Gilliam appointed Class III directors through 2028 annual meeting
  • Satpathy adds genomics, immunology, AI-enabled drug discovery and biotech venture expertise
Filed Aug 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue $151.0M, down from $172.9M, but underlying revenue excluding settlements grew 3% year over year
  • Consumables revenue $130.8M, up from $122.2M, offset by instrument revenue falling to $7.7M from $14.5M

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for the quarter ended June 30, 2026
  • Full revenue, earnings, guidance and operating details in Exhibit 99.1, the accompanying earnings release

AI summaries of TXG 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TXG

Don't miss the next TXG filing

  • Alerts as it files. A push when TXG files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TXG, by share count.
  • Ask anything. An AI agent that reads every TXG filing and answers with sources.

TXG alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Saxonov SergeSellNov 10, 2026$62.90
Saxonov SergeSellSep 22, 2026$79.62
SULIMAN SHEHNAAZSellSep 22, 2026$78.20
Saxonov SergeSellSep 22, 2026$81.83
Saxonov SergeSellSep 22, 2026$78.23
SULIMAN SHEHNAAZSellSep 22, 2026$79.51
Saxonov SergeSellSep 22, 2026$80.90
SULIMAN SHEHNAAZSellSep 22, 2026$81.67

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$618.7M$610.8M$642.8M
Gross Profit-$414.5M$443.9M
Operating Income--$194.6M-$61.0M
Net Income--$182.6M-$43.5M
Gross Margin-67.9%69.1%
Op. Margin--31.9%-9.5%
Net Margin--29.9%-6.8%
Balance Sheet
Total Assets-$918.6M$1.0B
Equity-$710.1M$796.3M
ROE--25.7%-5.5%
Per Share
EPS-$-1.52$-0.35
Cash Flow
Operating CF-$6.7M$136.1M
CapEx$48.6M$12.4M$5.9M

Source: XBRL data in 10x Genomics, Inc. (TXG)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TXG share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TXG shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202636$6.30B
Q2 202635$2.97B
Q1 202634$1.58B
Q4 202529$1.15B
Q3 202531$827.1M
Q2 202530$792.0M
Q1 202527$482.9M
Q4 202421$658.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 243 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TXG filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
10-QNov 6, 2026Analysis
8-KNov 5, 2026Analysis-
8-KNov 2, 2026Analysis-
4Sep 24, 2026--
4Sep 24, 2026--
4Sep 11, 2026--
4Sep 8, 2026--
SC 13GSep 8, 2026-
4Sep 3, 2026--
4Aug 28, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
4Aug 24, 2026--
4Aug 17, 2026--
4Aug 13, 2026--
10-QAug 7, 2026Analysis
8-KAug 6, 2026Analysis-
4Jun 24, 2026--
4Jun 18, 2026--
4Jun 8, 2026-
8-KJun 8, 2026Analysis
4Jun 8, 2026-

Related Health Care companies

All Health Care →

TXG SEC filings: frequently asked questions

Are TXG insiders buying or selling?

In the last 90 days, 10x Genomics, Inc. (TXG) officers, directors and 10% owners reported no open-market purchases and 25 open-market sales worth $12.6 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TXG stock?

As of September 30, 2026, the largest 10x Genomics, Inc. (TXG) holders among the 13F filers tracked by SignalX were T. Rowe Price Group ($1.6 billion), BlackRock ($1.0 billion), ARK Investment Management ($566.8 million), Vanguard Portfolio Management LLC ($534.5 million), Vanguard Capital Management LLC ($487.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TXG's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), 10x Genomics, Inc. (TXG) reported revenue of $642.8 million (up 5.2% from FY2024) and a net loss of $43.5 million. Diluted EPS was -$0.35. The figures come from the XBRL data in the 10-K.

What are the main risks in TXG's latest 10-K?

In the 10-K filed February 13, 2026, 10x Genomics, Inc. (TXG) flagged: Regulatory/legal risk: Patent litigation settlements with Vizgen (Feb 2025, $26M upfront) and Bruker (May 2025, $68M installments) impacting license and royalty revenue. Geopolitical/macroeconomic risk: Foreign currency fluctuations affecting revenue, mainly in euro, GBP, and JPY markets, causing realized/unrealized gains/losses of $4.6M in 2025. (AI summary of the Risk Factors section.)

What did TXG report in its latest 8-K?

10x Genomics, Inc. (TXG) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest TXG SEC filings?

10x Genomics, Inc. (TXG) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on November 6, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 13, 2026.

What is TXG's SEC CIK number?

10x Genomics, Inc. (TXG)'s SEC Central Index Key (CIK) is 1770787. EDGAR lists every TXG filing under that number.

Ask anything about TXG

The research agent reads TXG's filings, financials, insider trades and 13F holders, then answers with sources.